History

Pacific Edge was formed in February 2001 with the goal of developing simple-to-use,non-invasive, highly accurate diagnostic and prognostic tools for cancer. As a result of a successful research and product development programme, Pacific Edge currently has a pipeline of products for the early detection, and/or management of targeted cancers. clocktower

Pacific Edge Milestones
September 2006 Pacific Edge Biotechnology Licenses Multigene Colorectal Cancer Diagnostics for European Market
August 2005 $NZ 2.5 million of new capital raised through Rights Issue to existing shareholders.
May 2005 Technology for Business Growth grant of over $1 million awarded for development of gastric cancer tool.
May 2004 Heads of Agreement signed with large Japanese pharmaceutical company.
December 2003 Formal negotiations initiated with major Japanese pharmaceutical companies to co-develop and commercialise gastric and bladder cancer markers.
July 2003 Comprehensive patent application for potential gastric cancer diagnostic markers filed in the United States.
February 2003 Completion of IPO.
February 2002 Pacific Edge Biotechnology lists on the NZ Stock Exchange.
January 2002 PEB fully staffed with 10 FTEs.
World Class Scientific Advisory Board established.
August 2001 PEB established with NZ Seed Fund as its cornerstone shareholder and initial capital raising completed.
February 2001 PEB incorporated as a company.
February 2001 Intellectual Property identified and agreed to be acquired from the University of Otago.